EPCAM and neoplasm: This required the presence of a second activating αEpCAM–αCD3ε bsAb targeting an abundantly expressed tumor-associated antigen, whereas the mere crosslinking of EpCAM and CD28 by an αEpCAM–αCD28 bsAb was not sufficient (see Figure 6E).